The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its ...

In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...

Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

In a report released on January 7, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Moderna shares soared as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could ...

Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...